- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05577468
Efficacy and Safety of Tegoprazan Versus Esomeprazole-containing Bismuth Quadruple Therapy for Eradication of Helicobacter Pylori
A Multi-center, Randomized, Double-blind, Double-dummy Phase III Clinical Study to Evaluate the Efficacy and Safety of Tegoprazan Versus Esomeprazole-containing Bismuth Quadruple Therapy for Eradication of Helicobacter Pylori
This study is a multicenter, randomized, double-blind, double-dummy, phase III study to evaluate the efficacy and safety of tegoprazan versus esomeprazole-containing bismuth quadruple therapy in patients infected with Helicobacter pylori in China.
Screening phase: After signing the informed consent form, subjects will be determined for Helicobacter pylori infection by 13^C-urea breath test (UBT),histological testing and bacterial culture during the screening period. Subjects who meet all screening criteria will be randomized in a 1:1 ratio to receive the tegoprazan-containing bismuth quadruple therapy (hereinafter referred to as the tegoprazan group) or esomeprazole-containing bismuth quadruple therapy (hereinafter referred to as the esomeprazole group).
Treatment phase: Subjects will receive relevant study medication starting on Day 1 of the treatment period for 14 days.
Follow-up phase: Within 29+7 days after the last study drug treatment, subjects will return to the study site for efficacy and safety assessments. 13^C-UBT detection will be performed in this follow-up visit to determine the Hp infection status of the subjects after treatment.
Study Overview
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Zhong Chen
- Phone Number: +86-21-38867466
- Email: zhongchen@luoxin.cn
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100191
- Peking University Third Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
1) Subjects who volunteer to sign the written informed consent form approved by the Ethics Committee and agree to participate in this study prior to the initiation of any study procedures.
2) Subjects who are able to understand and follow the protocol requirements and agree to participate in all the study visits.
3) Males or females ≥18 years old and ≤70 years old. 4) In the screening stage, subjects are confirmed Hp infection by 13^C-urea breath test , histology test and bacterial culture, and then the investigators judge that Hp eradication treatment is required.
5) Subjects who agree to use appropriate medical method for contraception during the course of the study (not including women in medically sterile state)
Exclusion Criteria:
- 1) Subjects received Hp eradication treatment previously. 2) Subjects who have participated in other clinical studies within 4 weeks before screening, except for the following two situations:
- The study which the subject is participating or participated in is a non-interventional study (e.g. observational study or questionnaire survey); Subject had signed the informed consent form in that study, but withdrew from that study prior to the start of any treatment.
Subjects who have participated in the [NC821604] study and have demonstrated ulcer healing may participate in this study.
3) Subjects who participated in the planning and execution of this study. 4) Women who are pregnant or breastfeeding. 5) Subjects with known allergy to tegoprazan, esomeprazole, penicillins or other β-lactams, macrolide antibiotics or bismuth (including any related excipients). If a skin sensitivity test (skin test) is required, it should be carried out at Visit 1 according to routine medical practice.
6) Subjects with a history of drug (including but not limited to opioids) abuse or alcohol abuse within 1 year before the screening visit.
7) Subjects with Zollinger-Ellison syndrome. 8) Subjects who have previously undergone surgery or operations that may affect gastric acid secretion or drug absorption, 9) Subjects with "warning" symptoms such as painful swallowing, severe dysphagia, bleeding, weight loss, anemia, or blood in the stool that may indicate malignant lesions of the gastrointestinal tract, unless the possibility of malignant lesions is ruled out by endoscopy.
10) Subjects with a history of malignant tumor within 5 years before screening 11) Subjects who cannot undergo upper gastrointestinal endoscopy. 12) Subjects whose upper gastrointestinal endoscopy demonstrates acute upper gastrointestinal bleeding, active gastric ulcer or duodenal ulcer, acute gastric mucosal injury or duodenal mucosal injury.
13) Subjects with uncontrolled and unstable hepatic, renal, cardiovascular, respiratory, gastrointestinal, endocrine, hematologic, central nervous system or mental diseases as judged by investigators, in which participation in the study may affect the interpretation of their safety or research results.
14) Subjects who plan to be hospitalized for surgical treatment during the study.
15) Subjects who have taken H2 receptor antagonists or PPI within 14 days before the 13C-urea breath test during the screening period, or those who have taken antibacterial drugs, bismuth and certain Chinese medicines with antibacterial effects within 28 days before the 13C-urea breath test during the screening period.
16) Subjects who need to use the prohibited drugs listed in the protocol. 17) Subjects with any of the following laboratory test abnormalities at screening:
- AST > upper limit of normal (ULN);
- ALT > ULN;
- Total bilirubin > 1.2 × ULN;
Creatinine > 1.5 × ULN; 18) Subjects with clinically significant electrocardiogram (ECG) abnormalities at the screening as judged by investigators.
19) Human immunodeficiency virus (HIV) antibody positive, hepatitis B virus (HBV) surface antigen positive or hepatitis C virus (HCV) antibody positive confirmed by tests.
20) Judged by the investigator, there are other conditions compromising the subject's eligibility for this study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: tegoprazan
Participants will receive Tegoprazan tablets Esomeprazole magnesium enteric-coated tablets placebo Bismuth potassium citrate capsules Amoxicillin capsules Clarithromycin tablets
|
tegoprazan-containing bismuth quadruple therapy or Esomeprazole-containing bismuth quadruple therapy; Route of administration: oral;
|
Active Comparator: Esomeprazole
Participants will receive Tegoprazan tablets placebo Esomeprazole magnesium enteric-coated tablets Bismuth potassium citrate capsules Amoxicillin capsules Clarithromycin tablets
|
tegoprazan-containing bismuth quadruple therapy or Esomeprazole-containing bismuth quadruple therapy; Route of administration: oral;
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of All Participants With Successful Helicobacter Pylori (H.Pylori) Eradication
Time Frame: Day 29+7 days following the completion of treatment(duration of treatment was 2 weeks)
|
Percentage of all patients with Hp eradication determined by a 13^C-urea breath test after study treatment.
|
Day 29+7 days following the completion of treatment(duration of treatment was 2 weeks)
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Percentage of Participants With Successful Helicobacter Pylori (H.Pylori) Eradication in Participants With a Clarithromycin-resistant Strain of H Pylori at Baseline
Time Frame: Day 29+7 days following the completion of treatment( duration of treatment was 2 weeks)
|
Day 29+7 days following the completion of treatment( duration of treatment was 2 weeks)
|
Percentage of Participants With Successful Helicobacter Pylori (H.Pylori) Eradication in Participants With a Clarithromycin-sensitive Strain of H Pylori at Baseline
Time Frame: Day 29+7 days following the completion of treatment(duration of treatment was 2 weeks)
|
Day 29+7 days following the completion of treatment(duration of treatment was 2 weeks)
|
Percentage of Participants With Successful Helicobacter Pylori (H.Pylori) Eradication in Participants With a Amoxicillin-resistant Strain of H Pylori at Baseline
Time Frame: Day 29+7 days following the completion of treatment(duration of treatment was 2 weeks)
|
Day 29+7 days following the completion of treatment(duration of treatment was 2 weeks)
|
Percentage of Participants With Successful Helicobacter Pylori (H.Pylori) Eradication in Participants With a Amoxicillin-sensitive Strain of H Pylori at Baseline
Time Frame: Day 29+7 days following the completion of treatment(duration of treatment was 2 weeks)
|
Day 29+7 days following the completion of treatment(duration of treatment was 2 weeks)
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- NC822101
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Helicobacter Pylori Infection
-
Bangabandhu Sheikh Mujib Medical University, Dhaka...RecruitingHelicobacter Pylori Infection | Helicobacter Pylori EradicationBangladesh
-
Shandong UniversityRecruitingHelicobacter Pylori Infection | Patient Education | Helicobacter Pylori EradicationChina
-
Shandong UniversityCompletedHelicobacter Pylori Infection Helicobacter Pylori Eradication Patient EducationChina
-
Shanghai Jiao Tong University School of MedicineCompletedCure Rate of Helicobacter Pylori InfectionChina
-
Seoul National University Bundang HospitalRecruitingHelicobacter Pylori Infection | Helicobacter Pylori 23S rRNA Clarithromycin Resistance Mutation | Helicobacter Pylori Associated Gastrointestinal Disease | Helicobacter Pylori Infection, Susceptibility toKorea, Republic of
-
The First Affiliated Hospital of Nanchang UniversityUnknownBacterial Infection Due to Helicobacter Pylori (H. Pylori) | Eradication Therapy of Helicobacter Pylori | Detection of Helicobacter PyloriChina
-
Tanta UniversityNot yet recruitingPersistent Helicobacter Pylori InfectionEgypt
-
Nanjing First Hospital, Nanjing Medical UniversityCompletedHelicobacter Pylori 23S rRNA/gyrA Gene Mutation Detection Kit (Fluorescence PCR Fusion Curve Method)Helicobacter Pylori Infection | Helicobacter Pylori gyrA Levofloxacin Resistance Mutation | Fecal Drug Resistance Gene Detection | Helicobacter Pylori Infection, Susceptibility toChina
-
National University Hospital, SingaporeUnknownHELICOBACTER PYLORI INFECTIONSSingapore
-
Kaohsiung Veterans General Hospital.Kaohsiung Medical University Chung-Ho Memorial HospitalCompletedHelicobacter Pylori InfectionTaiwan
Clinical Trials on Tegoprazan
-
HK inno.N CorporationCompletedHealthyKorea, Republic of
-
HK inno.N CorporationUnknownHealthyKorea, Republic of
-
HK inno.N CorporationCompletedPharmacodynamics | Healthy Male VolunteersKorea, Republic of
-
Pusan National University HospitalCompletedThe Efficacy of Potassium-competitive Acid Blocker in Patients With Laryngopharyngeal Reflux DiseaseLaryngopharyngeal Reflux DiseaseKorea, Republic of
-
HK inno.N CorporationRecruitingHealthy | Hepatic ImpairmentKorea, Republic of
-
HK inno.N CorporationUnknownPharmacokinetics | Pharmacodynamics | Healthy Male VolunteersKorea, Republic of
-
HK inno.N CorporationCompleted
-
HK inno.N CorporationCompletedHelicobacter Pylori InfectionKorea, Republic of
-
HK inno.N CorporationEnrolling by invitationHealthyKorea, Republic of
-
HK inno.N CorporationNot yet recruitingHealthyKorea, Republic of